🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are on the rise globally, with estimates suggesting more than 82 million instances per year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the highly restricted available drugs at this time.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is also used to treat UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to see it through.

“This milestone signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Outcomes and Worldwide Availability

As per results detailed in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The research included hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to license and sell the drug in numerous developing nations.

Clinicians on the front lines have expressed hope. The availability of a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.